Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot help if intimacy became painful after menopause?
The O-Shot may be discussed for selected postmenopausal patients if painful intimacy is linked with local dryness, tissue fragility, lubrication, or sensitivity changes, but pain after menopause needs assessment first.
Direct answer
The O-Shot may be discussed for selected postmenopausal patients if painful intimacy is linked with local dryness, tissue fragility, lubrication, or sensitivity changes, but pain after menopause needs assessment first.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
Condition
Painful sex after menopause is largely driven by oestrogen deficiency, leading to thinned vaginal tissues and decreased lubrication.
Mechanism
The O-Shot isolates growth factors from the patient's blood, which trigger stem cells, promote collagen synthesis, and encourage.
Method
It is a non-surgical, non-hormonal outpatient procedure involving a blood draw, centrifugation, and local injections [1, 2, 10].
Outcomes
Benefits often include reduced pain during intercourse, improved natural lubrication, enhanced tissue elasticity, and increased sexual sensitivity [2.
Important safety note
reported safety profile: Because the PRP is autologous (derived from the patient's own body), there is an exceptionally low risk of allergic reactions or rejection [20-22].
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
Investigational Status: While patient satisfaction is high and early pilot studies show promising results, high-quality, large-scale, randomised controlled trials (RCTs) are still limited [32-35]. Guidelines: Major medical organisations currently view energy-based and PRP therapies for GSM as experimental and do not recommend them as standard first-line options over traditional treatments [32, 36].
Clinical context
Investigational Status: While patient satisfaction is high and early pilot studies show promising results, high-quality, large-scale, randomised controlled trials (RCTs) are still limited [32-35].
Evidence
Symptoms
Alternatives
What it means
Investigational Status: While patient satisfaction is high and early pilot studies show promising results, high-quality, large-scale, randomised controlled trials (RCTs) are still limited [32-35].
Why it happens
Guidelines: Major medical organisations currently view energy-based and PRP therapies for GSM as experimental and do not recommend them as standard first-line options over traditional treatments [32, 36].
Evidence limits
First-Line Standard of Care: Low-dose topical vaginal oestrogen and non-hormonal moisturisers remain the most evidence-backed first-line treatments for postmenopausal vaginal pain and atrophy [37, 38].
Treatment fit
Efficacy Rate: Clinical observations suggest that 60% to 85% of women report symptom improvement, meaning a subset of patients may not experience noticeable changes [18].
What this means in practice
Costs should be confirmed on the /pricing/ page before booking
Procedure Time: The entire treatment takes roughly 30 to 60 minutes in a clinic [12, 13]. Initial Results: Some patients report improvements in lubrication and sensitivity within a few days to weeks [11, 12, 14, 15].
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
Investigational Status: While patient satisfaction is high and early pilot studies show promising results, high-quality, large-scale, randomised controlled trials (RCTs) are still limited [32-35].
It protects safety
reported safety profile: Because the PRP is autologous (derived from the patient's own body), there is an exceptionally low risk of allergic reactions or rejection [20-22].
It reviews alternatives
Cost: The procedure is elective and generally not covered by medical insurance [25, 39, 40].
It sets expectations
Procedure Time: The entire treatment takes roughly 30 to 60 minutes in a clinic [12, 13].
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Costs should be confirmed on the /pricing/ page before booking
Consultation priorities
Consultation: The process begins with a medical review to discuss symptoms, rule out other pathologies, and set realistic expectations [27, 44].
Consent
Aftercare
Follow-up
Before treatment
Consultation: The process begins with a medical review to discuss symptoms, rule out other pathologies, and set realistic expectations [27, 44].
During care
Blood Draw: A small sample of blood (similar to a standard lab test) is drawn from the patient's arm [4, 10, 44].
Aftercare
Processing: The blood is placed in a specialised centrifuge for 5 to 15 minutes to isolate and concentrate the platelet-rich plasma [27, 44, 46].
When to reassess
Preparation: A strong topical anaesthetic cream or local numbing injection is applied to the vaginal and clitoral areas to minimise discomfort [23, 27, 44].
Practical expectations
Procedure Time: The entire treatment takes roughly 30 to 60 minutes in a clinic [12, 13].
Downtime: There is usually little recovery time required. Most women can return to work and daily activities immediately [12, 27, 43].
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Painful sex after menopause is inevitable.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: PRP replaces a menopause review.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: All postmenopausal pain is dryness.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Guidelines: Major medical organisations currently view energy-based and PRP therapies for GSM as experimental and do not recommend them as standard first-line options over traditional treatments [32, 36].
Alternatives
Cost: The procedure is elective and generally not covered by medical insurance [25, 39, 40].
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
reported safety profile: Because the PRP is autologous (derived from the patient's own body), there is an exceptionally low risk of allergic reactions or rejection [20-22].
Are alternatives clear?
Cost: The procedure is elective and generally not covered by medical insurance [25, 39, 40].
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
reported safety profile: Because the PRP is autologous (derived from the patient's own body), there is an exceptionally low risk of allergic reactions or rejection [20-22].
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
reported safety profile: Because the PRP is autologous (derived from the patient's own body), there is an exceptionally low risk of allergic reactions or rejection [20-22].
Bleeding or discharge
Mild Side Effects: Patients may experience temporary soreness, mild swelling, localised tenderness, or light spotting for 1 to 2 days following the injections [23-26].
Infection signs
Contraindications: The O-Shot is not recommended for women with active vaginal or pelvic infections, blood clotting disorders, severe anemia, or active gynecological cancers without oncological clearance [27-29].
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The best page feels clinically adult: it validates the symptom, explains the biology, and presents PRP as a possible assessed option rather than a shortcut.
Clinical reality
- Investigational Status: While patient satisfaction is high and early pilot studies show promising results, high-quality, large-scale, randomised controlled trials (RCTs) are still limited [32-35].
- Guidelines: Major medical organisations currently view energy-based and PRP therapies for GSM as experimental and do not recommend them as standard first-line options over traditional treatments [32, 36].
- First-Line Standard of Care: Low-dose topical vaginal oestrogen and non-hormonal moisturisers remain the most evidence-backed first-line treatments for postmenopausal vaginal pain and atrophy [37, 38].
- Efficacy Rate: Clinical observations suggest that 60% to 85% of women report symptom improvement, meaning a subset of patients may not experience noticeable changes [18].
Timeline and expectations
- Procedure Time: The entire treatment takes roughly 30 to 60 minutes in a clinic [12, 13].
- Initial Results: Some patients report improvements in lubrication and sensitivity within a few days to weeks [11, 12, 14, 15].
- Peak Results: The peak reported response and relief from painful intercourse are typically seen 3 to 4 months after the injection [14, 16, 17].
- Longevity: Results vary based on individual physiological factors but generally last between 12 and 18 months, with some women experiencing benefits for up to 1 to 4 years [14, 18, 19].
- Maintenance: Repeat maintenance treatments are often recommended every 12 to 18 months to sustain the effects [18, 19].
Practical logistics
- Cost: The procedure is elective and generally not covered by medical insurance [25, 39, 40].
- Downtime: There is usually little recovery time required. Most women can return to work and daily activities immediately [12, 27, 43].
- Resuming Intimacy: Depending on the provider's protocol, patients are usually cleared to resume sexual activity either the same day, or after a brief 48-hour resting period [43-45].
Research sources
- Runels, C., et al. (2014). "A Pilot Study of the Effect of localised Injections of Autologous Platelet Rich Plasma (PRP) for the Treatment of Female Sexual Dysfunction." Journal of Women's Health Care [51].
- Sukgen, G., et al. (2020). "Platelet-rich plasma administration to the lower anterior vaginal wall to improve female sexuality satisfaction." Turkish Journal of Obstetrics and gynaecology [52].
- Dankova, I., et al. (2023). "Efficacy and Safety of Platelet-Rich Plasma Injections for the Treatment of Female Sexual Dysfunction and Stress Urinary Incontinence: A Systematic Review." Biomedicines [53].
- Atlihan, U., et al. (2025). "Comparison of topical oestrogen and platelet-rich plasma injections in the treatment of postmenopausal vaginal atrophy." Frontiers in Medicine [54].
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE interventional procedures guidance
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 420 imported records. Additional reviewed material included UK clinical guidance, professional society guidance, peer-reviewed clinical papers, evidence reviews; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. The information provided in this payload is for educational and informational purposes only and does not constitute medical advice. The O-Shot is an off-label procedure and its efficacy is still under clinical investigation. Patients should always consult with a licensed, appropriately qualified healthcare provider to accurately diagnose the cause of painful intimacy and determine the most appropriate, individualised treatment plan. Results vary. Not a cure.
